Drug Trial Radar · NCT02842086
Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex With Men and Are At Risk of HIV-1 Infection
Last checked: Nov 19, 2026Latest source record: Sep 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
5,399
Actual
Start
Sep 2, 2016
Primary completion
Jan 31, 2019
Study completion Jul 29, 2026
Sponsor
- Lead sponsor
- Gilead SciencesGilead Sciences (GILD)
- Sponsor type
- Industry
- First posted
- Jul 22, 2016
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The primary objective of this study is to assess the rates of HIV-1 infection in Men (MSM) and transgender women (TGW) who have sex with men and who are administered daily emtricitabine/tenofovir alafenamide (F/TAF) or emtricitabine/tenofovir disoproxil fumarate (F/TDF) with a minimum follow-up of 48 weeks and at least 50% of participants have 96 weeks of follow-up after randomization.
Conditions
- Pre-Exposure Prophylaxis of HIV-1 Infection
Interventions
F/TAFDrug
200/25 mg tablet administered orally once daily
F/TDFDrug
200/300 mg tablet administered orally once daily
F/TAF PlaceboDrug
Tablet administered orally once daily
F/TDF PlaceboDrug
Tablet administered orally once daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of HIV-1 Infection Per 100 Person Years (PY)Time frame: When all participants completed minimum follow-up of 48 weeks and at least 50% of the participants completed 96 weeks of follow-up after randomization or permanently discontinued from the study (maximum 125 weeks)
Locations
93 sites in 11 countries. Site status is shown where the registry gives one.
Site not named
Beverly Hills, California
Site not named
Los Angeles, California
Site not named
Los Angeles, California
Site not named
Newport Beach, California
Site not named
Oakland, California
Site not named
Sacramento, California
Site not named
Sacramento, California
Site not named
San Diego, California
Site not named
San Francisco, California
Site not named
San Francisco, California
Site not named
San Francisco, California
Site not named
Torrance, California
Site not named
Aurora, Colorado
Site not named
Denver, Colorado
Site not named
New Haven, Connecticut
Site not named
Washington D.C., District of Columbia
Site not named
Washington D.C., District of Columbia
Site not named
Fort Lauderdale, Florida
Site not named
Fort Lauderdale, Florida
Site not named
Ft. Pierce, Florida
Site not named
Miami, Florida
Site not named
Orlando, Florida
Site not named
Pensacola, Florida
Site not named
West Palm Beach, Florida
Site not named
Atlanta, Georgia
Site not named
Atlanta, Georgia
Site not named
Atlanta, Georgia
Site not named
Macon, Georgia
Site not named
Chicago, Illinois
Site not named
Chicago, Illinois
Site not named
New Orleans, Louisiana
Site not named
Boston, Massachusetts
Site not named
Springfield, Massachusetts
Site not named
Berkley, Michigan
Site not named
Detroit, Michigan
Site not named
Minneapolis, Minnesota
Site not named
Las Vegas, Nevada
Site not named
Somers Point, New Jersey
Site not named
Santa Fe, New Mexico
Site not named
New York, New York
Showing 40 of 93 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.